key: cord-0854803-fxwsfa89
authors: Scioscia, M; Noventa, M; Palomba, S; Laganà, AS
title: Effect of the COVID‐19 pandemic on oncology screenings: it is time to change course
date: 2021-08-17
journal: BJOG
DOI: 10.1111/1471-0528.16857
sha: 6406db1510d50dc465f0eaa3b6b08fbcb355688c
doc_id: 854803
cord_uid: fxwsfa89

nan

We have found that the COVID-19 pandemic has had a significant negative effect on oncology screenings. Although this issue is well known to clinicians, the actual impact is less clear.

In most countries, national health services offer cancer screening programmes for breast, colon and cervical cancer. These secondary prevention measures are considered an integral part of treatment in oncology. Although cancer treatment has been guaranteed during the COVID-19 pandemic, screenings have been suspended and/or severely reduced worldwide during the first and second waves due to the reprioritisation of health services, 1 as was clearly highlighted by Meggetto et al. 2 In a report about a cervical screening programme in Ontario, recent data on the effect of screening discontinuation during the first wave demonstrated increased delays in cancer diagnosis and treatment. Notably, population-based studies reported a 30% reduction in primary care consultations and a 12-15% reduction in the number of referrals for both colorectal and breast cancer, with a significant increase in more advanced stages of disease compared with the same period in 2019. 2, 3 National data in Italy showed a significant reduction in the number of screening tests performed between January and September 2020 compared with the same months in 2019 (Table 1 ). This was due to the suspension of booked screenings and also to a reduction in adherence to screenings, probably as a consequence of fear of COVID-19 (À17%, À21% and À20% for cervical, breast and colorectal cancer, respectively). Although we can justify the decrease in the number of tests (between 54% and 58%) during the first wave of the pandemic (January to May), the second period assessed before the second wave (June to September) still showed a significant reduction (between 28% and 46%) in adherence to screening.

This led to a cumulative delay of an estimated 4 months or more, more than 6300 missed diagnoses of cervical, breast and colorectal cancer and 6600 precancerous colorectal lesions. Similar data may be expected during the second wave of the pandemic, increasing delay and missed diagnoses.

The discontinuation of the programme during the second wave of the COVID-19 pandemic may lead to a www.bjog.org significant number of patients going undetected and untreated, thereby resulting in a further delay in diagnosing early stages of cancer. This may contribute to an increase in diagnoses of invasive cancer instead of precancerous lesions, and thus more advanced stages of the disease in the coming years. This would be accompanied by worse cancer prognoses and an increased need for more extensive treatments. According to recent data 4 it is likely that the delay will not be rectified for many years. It is politically challenging to prioritise secondary prevention during this second wave of the pandemic. However, it is necessary to make up for lost time and to prevent catastrophic scenarios in the coming years.

None declared. Completed disclosure of interests form available to view online as supporting information.

Data sharing is not applicable to this article as no new data were created or analysed in this study.

Additional supporting information may be found online in the Supporting 

Impact of the COVID-19 pandemic on the symptomatic diagnosis of cancer: the view from primary care

The impact of the COVID-19 pandemic on the Ontario Cervical Screening Program, colposcopy and treatment services in Ontario, Canada: a population-based study

Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era

Delays and disruptions in cancer health care due to COVID-19 pandemic: systematic review